Compare HFWA & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HFWA | MGTX |
|---|---|---|
| Founded | 1927 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1997 | 2018 |
| Metric | HFWA | MGTX |
|---|---|---|
| Price | $28.36 | $13.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $30.50 | $24.57 |
| AVG Volume (30 Days) | 265.8K | ★ 686.9K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ 58.06 | 33.02 |
| EPS | 0.90 | ★ 1.30 |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | $45.85 | $141.38 |
| Revenue Next Year | $7.83 | N/A |
| P/E Ratio | $32.11 | ★ $10.41 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $21.32 | $6.62 |
| 52 Week High | $31.25 | $15.35 |
| Indicator | HFWA | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.15 | 47.52 |
| Support Level | $26.53 | $12.39 |
| Resistance Level | $28.52 | $15.33 |
| Average True Range (ATR) | 0.42 | 0.64 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 3.13 | 9.20 |
Heritage Financial Corp is a bank holding company. The company, through its subsidiary, provides commercial lending and deposit relationships with small businesses and their owners in its market areas and attracts deposits from the general public. It accepts various deposit products, such as non-interest demand accounts, money market accounts, savings accounts, and certificates of deposit. Besides, the Bank also makes real estate construction loans, land development loans, and consumer loans, and originates first mortgage loans on residential properties mainly located in its market area. Geographically, all the business activity functions through the region of the United States.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.